5 / 5
Note:
Page 26
May 22-23, 2019 | Rome, Italy
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
IMMUNOLOGY
AND CANCER THERAPY
2
nd
Global Summit on
Immunotherapy 2019
Immunology Case Reports | Volume 3
Accepted Abstract
TREATMENT OF TNBC USED BY RSC001
Zheng Shuo Jin
Tsinghua University, China
I
n several cases, traditional cancer treatment can cause many side effects both in short and long term prob-
lems that occur when affect healthy tissues and organs. Because of the traditional surgical treatment only, can
remove the tumor that has been formed, it cannot completely prevent cancer metastasis or growth. Although
chemotherapy can increase the survival rate of patients with surgical treatment, it still cannot completely in-
hibit tumor growth. Therefore, in order to completely suppress the development of cancer cells, the research
and application of immunotherapy have attracted more and more people’s attention, using T cell in autoim-
mune system to attack tumor cell also using small molecular in tumor cell cycle as a targeting. The classic
pathway JAK-STAT induces chemokines expression, chemokines CXCL10 and CXCL11 will recruit CD8+ T cell
for attacking tumor cell. STAT1 and STAT3 are different transcription factor in this pathway. We found a small
molecule RSC001 should interact with this pathway and chemokines; it should be affecting the effect of immu-
notherapy or can be a new targeting point for cancer immunotherapy in future.
Immunol Case Rep 2019, Volume 3 | DOI: 10.4066/2591-7366-C2-006